A detailed history of Alpha Mark Advisors, LLC transactions in Incyte Corp stock. As of the latest transaction made, Alpha Mark Advisors, LLC holds 75 shares of INCY stock, worth $5,402. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75
Previous 75 -0.0%
Holding current value
$5,402
Previous $5,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 28, 2023

SELL
$60.95 - $75.51 $6,095 - $7,551
-100 Reduced 57.14%
75 $5,000
Q1 2023

May 04, 2023

SELL
$70.23 - $86.01 $7,023 - $8,601
-100 Reduced 36.36%
175 $13,000
Q2 2022

Aug 11, 2022

SELL
$66.18 - $83.18 $13,236 - $16,636
-200 Reduced 42.11%
275 $21,000
Q1 2022

May 02, 2022

SELL
$66.02 - $79.71 $330 - $398
-5 Reduced 1.04%
475 $38,000
Q4 2021

Feb 09, 2022

BUY
$63.34 - $74.11 $30,403 - $35,572
480 New
480 $35,000
Q3 2020

Nov 06, 2020

SELL
$85.07 - $109.69 $11,144 - $14,369
-131 Closed
0 $0
Q1 2020

Apr 24, 2020

BUY
$63.18 - $85.97 $8,276 - $11,262
131 New
131 $10,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Alpha Mark Advisors, LLC Portfolio

Follow Alpha Mark Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Mark Advisors, LLC with notifications on news.